G-BA - Gemeinsamer Bundesausschuss

Try a search

• What added benefit did G-BA grant pembrolizumab in its latest assessments?
• Which orphan drugs got a considerable added benefit from G-BA in 2026?
• Compare the G-BA added benefit and comparator for semaglutide patient groups
• Which G-BA benefit assessment procedures had news this week?

Tools (3)

1. listGbaProcedureUpdatesList the latest events in G-BA benefit assessment procedures (about the 10 most recent): procedure started, dossier and IQWiG benefit assessment published with the comment deadline, procedure completed. Use for 'what changed recently' questions and for ongoing procedures not yet decided; decisions themselves are in searchGbaBenefitAssessments about a month after they are taken. Event texts are in German.Free
2. getGbaBenefitAssessmentGet full G-BA early benefit assessment decisions (AMNOG) by decision id: per patient group the comparator therapy, added-benefit category and certainty, the benefit statement, results per endpoint category (mortality, morbidity, quality of life, side effects) and G-BA's summary of reasons, plus ICD-10 codes and approval flags. Takes decisionIds from searchGbaBenefitAssessments.Free
3. searchGbaBenefitAssessmentsSearch German G-BA early benefit assessment decisions (AMNOG, § 35a SGB V) by active substance (INN), trade name, ATC code, indication, added-benefit category and decision date. Returns, for each decision, the added-benefit category and certainty per patient group vs the appropriate comparator therapy. Use the decisionIds with getGbaBenefitAssessment for endpoint results and G-BA's reasons. Only decisions still in force are covered (repealed or superseded ones are dropped by G-BA); indication texts are in German, and substance matching tolerates English INN spelling (semaglutide finds Semaglutid). Prefer atcCode for cross-country joins.Free